The CoroNAb consortium comprises researchers from:
Karolinska Institutet (Sweden)
Statens Serum Institut (Denmark)
ETH Zurich (Switzerland)
Imperial College London (The United Kingdom)
CoroNAb is engaged in research aiming to understand SARS-CoV-2 and COVID-19.
To investigate protein subunit immunization strategies that elicit antibodies that neutralize SARS-CoV-2.
To identify and study, in detail, the antibodies that are elicited by such immunization strategies.
To identify and characterize alpaca single-domain antibodies that can bind to and neutralize SARS-CoV-2.
To investigate new technologies for antibody optimization.
To model pandemic dynamics and the potential effects of interventions.